
- /
- Supported exchanges
- / US
- / PASG.NASDAQ
Passage Bio Inc (PASG NASDAQ) stock market data APIs
Passage Bio Inc Financial Data Overview
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Passage Bio Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Passage Bio Inc data using free add-ons & libraries
Get Passage Bio Inc Fundamental Data
Passage Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -52 485 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.202
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Passage Bio Inc News

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative disease...


Canaccord Genuity lowers Passage Bio stock price target to $67 from $260
Investing.com - Canaccord Genuity lowered its price target on Passage Bio Inc. (NASDAQ:PASG) to $67.00 from $260.00 on Thursday, while maintaining a Buy rating on the stock. Currently trading at $6.38...

Passage Bio GAAP EPS of -$2.96 beats by $1.08
* Passage Bio press release [https://seekingalpha.com/pr/20197173-passage-bio-reports-second-quarter-2025-financial-results-and-provides-recent-business] (NASDAQ:PASG [https://seekingalpha.com/symbo...

Friday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SMX [https://www.chartmill.com/st...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.